Journal: Eye

Article Title: The effect of initial intravitreal tissue plasminogen activator and gas injection on vision improvement in patients with submacular haemorrhage associated with age-related macular degeneration

doi: 10.1038/s41433-020-01383-z

Figure Lengend Snippet: A Optical coherence tomography (OCT) images at Initial visit and 1 week after intravitreal t-PA and gas injection as an initial treatment for submacular haemorrhage (SMH). In a week, SMH successfully migrated to peripheral area from the foveal centre. B OCT at initial visit and 1 month after anti-vascular endothelial growth factor antibody injection. The SMH remained similar for 1 month.

Article Snippet: After 5 min, intravitreal gas injection (0.3 mL of 100% C 3 F 8 gas; Matheson Tri-Gas, Montgomeryville, PA, USA) was performed, followed by anterior chamber paracentesis to reduce the intraocular pressure.

Techniques: Tomography, Injection

Journal: Eye

Article Title: The effect of initial intravitreal tissue plasminogen activator and gas injection on vision improvement in patients with submacular haemorrhage associated with age-related macular degeneration

doi: 10.1038/s41433-020-01383-z

Figure Lengend Snippet: Baseline characteristics in intravitreal tissue plasminogen activator and gas injection group (Group 1) and anti-vascular endothelial growth factor injection group (Group 2) as an initial treatment.

Article Snippet: After 5 min, intravitreal gas injection (0.3 mL of 100% C 3 F 8 gas; Matheson Tri-Gas, Montgomeryville, PA, USA) was performed, followed by anterior chamber paracentesis to reduce the intraocular pressure.

Techniques: Injection

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Article Title: Ranibizumab

doi: 10.1177/8755122515599552

Figure Lengend Snippet: Anti-VEGF Drugs: FDA-Labeled Indications and Non-FDA-Labeled Indications.

Article Snippet: NCT0047333 25 , III , Genentech, Inc , • Ranibizumab 0.3 mg monthly intravitreal injection for 36 months , Percentage of patients who gained ≥15 letters in BCVA score from baseline at month 24 , Complete.

Techniques:

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Article Title: Ranibizumab

doi: 10.1177/8755122515599552

Figure Lengend Snippet: Completed and Uncompleted Clinical Trials Evaluating the Efficacy of Ranibizumab for Diabetic Retinopathy.

Article Snippet: NCT0047333 25 , III , Genentech, Inc , • Ranibizumab 0.3 mg monthly intravitreal injection for 36 months , Percentage of patients who gained ≥15 letters in BCVA score from baseline at month 24 , Complete.

Techniques: Injection, Functional Assay, Modification